H&Q Round-up

Written byJustin Silver

| 1 min read

Listen with Speechify

0:00

1:00

A week later: I have been revitalized and am sitting comfortably in my office at Ferghana Partners in New York. I have written 50 meeting memo?s and have cultivated some very interesting new business. H&Q 2006 was an incredible success! Looking back on the conference, I think 2006 is poised to be an incredible year in the biotechnology industry: I am excited to do business and so are others. Although it is tougher for companies to go public?valuation expectations have been tough to swallow for several private companies?we are still situated in the longest IPO window in industry history and companies remain steadfast in hitting clinical, financial and strategic milestones. M&A will continue to be hot; companies are receiving higher valuations than in the public markets and investors will continue to take advantage of the high returns. Corporate partnering for biotechnology companies will also increase in terms of number of deals consummated and deal size. Big Pharma?s pipelines are running out of products and the need for outsourced innovation is at an all time high. Biotech CEO?s know this, and will make the most of their negotiation position by maximizing deal terms. As for me, I will keep pushing my transactions through the pipeline and developing new business. See you at the next conference!

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member?